2nd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$670,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform legislation; implementation of biologics provisions of healthcare reform legislation; H.R.5, Help Efficient, Accessible, Low-Cost, Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse and drug diversion proposals.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: SENATE; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS)

Bills named: H.R. 5 (112th), S. 296 (112th)

Pharmacy PHA

Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protrection Recall Act of 2011; Medicaid pharmacy issues.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 330 (112th)

Trade (domestic/foreign) TRD

U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —

Contacted: White House Office; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Copyright/Patent/Trademark CPT

S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT JOHN CLARK —
ROBERT FALB —
TERRI STEWART —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR); White House Office

Bills named: S. 23 (112th), S. 27 (112th), H.R. 1249 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.